JP2014515373A - 多発性硬化症の治療方法およびミエリン量を保存および／または増加させる方法 - Google Patents
多発性硬化症の治療方法およびミエリン量を保存および／または増加させる方法 Download PDFInfo
- Publication number
- JP2014515373A JP2014515373A JP2014512168A JP2014512168A JP2014515373A JP 2014515373 A JP2014515373 A JP 2014515373A JP 2014512168 A JP2014512168 A JP 2014512168A JP 2014512168 A JP2014512168 A JP 2014512168A JP 2014515373 A JP2014515373 A JP 2014515373A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- fumarate
- years
- treatment
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 112
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 52
- 102000006386 Myelin Proteins Human genes 0.000 title claims abstract description 19
- 108010083674 Myelin Proteins Proteins 0.000 title claims abstract description 19
- 210000005012 myelin Anatomy 0.000 title claims abstract description 19
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims abstract description 207
- 229960004419 dimethyl fumarate Drugs 0.000 claims abstract description 206
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 122
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 112
- 230000003902 lesion Effects 0.000 claims abstract description 81
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims abstract description 65
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims abstract description 65
- 230000005713 exacerbation Effects 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims description 133
- 239000000902 placebo Substances 0.000 claims description 72
- 229940068196 placebo Drugs 0.000 claims description 72
- 230000007423 decrease Effects 0.000 claims description 49
- 230000009467 reduction Effects 0.000 claims description 46
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 44
- 230000002829 reductive effect Effects 0.000 claims description 44
- 230000008859 change Effects 0.000 claims description 31
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 229940005650 monomethyl fumarate Drugs 0.000 abstract description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 21
- 208000035475 disorder Diseases 0.000 abstract description 6
- 229910052688 Gadolinium Inorganic materials 0.000 abstract description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 abstract description 2
- 238000009522 phase III clinical trial Methods 0.000 description 22
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 17
- 108010072051 Glatiramer Acetate Proteins 0.000 description 16
- 229960003776 glatiramer acetate Drugs 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 13
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000001530 fumaric acid Substances 0.000 description 8
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 229940121164 dimethyl fumarate 240 mg Drugs 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000002595 magnetic resonance imaging Methods 0.000 description 6
- 206010063659 Aversion Diseases 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 208000016192 Demyelinating disease Diseases 0.000 description 4
- 206010012305 Demyelination Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000003862 health status Effects 0.000 description 4
- 230000005415 magnetization Effects 0.000 description 4
- -1 poly (ethylene) Polymers 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000004885 white matter Anatomy 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- OEIQOKPNLCRCFM-YBFXNURJSA-N 1-[(E)-(1,3-benzothiazol-2-ylhydrazinylidene)methyl]naphthalen-2-ol Chemical compound Oc1ccc2ccccc2c1\C=N\N=c1\[nH]c2ccccc2s1 OEIQOKPNLCRCFM-YBFXNURJSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101001013647 Mus musculus Methionine synthase Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010072731 White matter lesion Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002884 effect on inflammation Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000007101 progressive neurodegeneration Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490572P | 2011-05-26 | 2011-05-26 | |
| US61/490,572 | 2011-05-26 | ||
| US201261625624P | 2012-04-17 | 2012-04-17 | |
| US61/625,624 | 2012-04-17 | ||
| PCT/US2012/039721 WO2012162669A1 (en) | 2011-05-26 | 2012-05-25 | Methods of treating multiple sclerosis and preserving and/or increasing myelin content |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014515373A true JP2014515373A (ja) | 2014-06-30 |
| JP2014515373A5 JP2014515373A5 (https=) | 2015-07-16 |
Family
ID=47217796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512168A Pending JP2014515373A (ja) | 2011-05-26 | 2012-05-25 | 多発性硬化症の治療方法およびミエリン量を保存および／または増加させる方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140163100A1 (https=) |
| EP (1) | EP2713724A4 (https=) |
| JP (1) | JP2014515373A (https=) |
| KR (1) | KR20140036257A (https=) |
| CN (1) | CN103732062A (https=) |
| AU (1) | AU2012258558A1 (https=) |
| BR (1) | BR112013030169A2 (https=) |
| CA (1) | CA2836480A1 (https=) |
| CL (1) | CL2013003358A1 (https=) |
| CO (1) | CO6811862A2 (https=) |
| EA (1) | EA201391578A1 (https=) |
| EC (1) | ECSP13013117A (https=) |
| IL (1) | IL229448A0 (https=) |
| MX (1) | MX2013013781A (https=) |
| PE (1) | PE20141316A1 (https=) |
| PH (1) | PH12013502443A1 (https=) |
| SG (1) | SG195049A1 (https=) |
| WO (1) | WO2012162669A1 (https=) |
| ZA (1) | ZA201308681B (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170095302A (ko) * | 2014-12-11 | 2017-08-22 | 액테리온 파마슈티칼 리미티드 | 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물 |
| JP2017533954A (ja) * | 2014-10-27 | 2017-11-16 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩 |
| US12336980B2 (en) | 2014-12-11 | 2025-06-24 | Vanda Pharmaceuticals Inc. | Dosing regimen for a selective S1P1 receptor agonist |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2526586C (en) | 2003-09-09 | 2010-03-16 | Biogen International Gmbh | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| PL2316430T3 (pl) | 2004-10-08 | 2012-11-30 | Forward Pharma As | Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego |
| RU2554347C2 (ru) | 2008-08-19 | 2015-06-27 | Ксенопорт, Инк. | Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения |
| KR20150080037A (ko) | 2011-06-08 | 2015-07-08 | 바이오젠 엠에이 인코포레이티드 | 고순도 및 결정질 다이메틸 푸마레이트의 제조 방법 |
| US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| CA2882730C (en) | 2012-08-22 | 2019-12-31 | Arbor Pharmaceuticals, Llc | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| WO2014031901A1 (en) * | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of use for monomethyl fumarate and prodrugs thereof |
| EP2934503B1 (en) | 2012-12-21 | 2019-04-10 | Biogen MA Inc. | Deuterium substituted fumarate derivatives |
| KR102085557B1 (ko) | 2013-03-14 | 2020-03-06 | 엘커메스 파마 아일랜드 리미티드 | 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도 |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| US9416096B2 (en) | 2013-09-06 | 2016-08-16 | Xenoport, Inc. | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
| CN103724198A (zh) * | 2013-11-28 | 2014-04-16 | 镇江圣安医药有限公司 | 富马酸二甲酯的新型衍生物及其应用 |
| JP6337135B2 (ja) | 2014-02-24 | 2018-06-06 | アルカーメス ファーマ アイルランド リミテッド | フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用 |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| ES2713157T3 (es) | 2014-02-28 | 2019-05-20 | Banner Life Sciences Llc | Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| MA40985A (fr) * | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| GB201907882D0 (en) | 2019-06-03 | 2019-07-17 | Cyprus Foundation For Muscular Dystrophy Res | Methods |
| US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19721099C2 (de) * | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| CN101056624A (zh) * | 2004-10-08 | 2007-10-17 | Adi技术制药股份公司 | 包含富马酸酯的控释药物组合物 |
| WO2007042034A1 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| ES2599227T3 (es) * | 2007-02-08 | 2017-01-31 | Biogen Ma Inc. | Neuroprotección en enfermedades desmielinizantes |
| EP2680010A1 (en) * | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Nrf2 screening assays and related methods and compositions |
| RU2554347C2 (ru) * | 2008-08-19 | 2015-06-27 | Ксенопорт, Инк. | Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения |
| JP2012525385A (ja) * | 2009-04-29 | 2012-10-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 神経変性および神経炎症の治療 |
-
2012
- 2012-05-25 EP EP12789291.7A patent/EP2713724A4/en not_active Withdrawn
- 2012-05-25 BR BR112013030169A patent/BR112013030169A2/pt not_active IP Right Cessation
- 2012-05-25 CN CN201280036988.6A patent/CN103732062A/zh active Pending
- 2012-05-25 US US14/119,373 patent/US20140163100A1/en not_active Abandoned
- 2012-05-25 SG SG2013085667A patent/SG195049A1/en unknown
- 2012-05-25 EA EA201391578A patent/EA201391578A1/ru unknown
- 2012-05-25 JP JP2014512168A patent/JP2014515373A/ja active Pending
- 2012-05-25 PH PH1/2013/502443A patent/PH12013502443A1/en unknown
- 2012-05-25 WO PCT/US2012/039721 patent/WO2012162669A1/en not_active Ceased
- 2012-05-25 AU AU2012258558A patent/AU2012258558A1/en not_active Abandoned
- 2012-05-25 PE PE2013002710A patent/PE20141316A1/es not_active Application Discontinuation
- 2012-05-25 CA CA2836480A patent/CA2836480A1/en not_active Abandoned
- 2012-05-25 MX MX2013013781A patent/MX2013013781A/es unknown
- 2012-05-25 KR KR1020137034196A patent/KR20140036257A/ko not_active Withdrawn
-
2013
- 2013-11-14 IL IL229448A patent/IL229448A0/en unknown
- 2013-11-19 ZA ZA2013/08681A patent/ZA201308681B/en unknown
- 2013-11-22 CL CL2013003358A patent/CL2013003358A1/es unknown
- 2013-11-26 CO CO13277997A patent/CO6811862A2/es not_active Application Discontinuation
- 2013-12-26 EC ECSP13013117 patent/ECSP13013117A/es unknown
Non-Patent Citations (2)
| Title |
|---|
| JPN5014006851; ＫＡＰＰＯＳ ＬＵＤＷＩＧ: 'ＥＦＦＩＣＡＣＹ ＡＮＤ ＳＡＦＥＴＹ ＯＦ ＯＲＡＬ ＦＵＭＡＲＡＴＥ ＩＮ ＰＡＴＩＥＮＴＳ ＷＩＴＨ ＲＥＬＡＰＳＩＮＧ-ＲＥＭＩＴＴＩＮＧ ＭＵＬＴＩＰＬＥ 以下備考' ＬＡＮＣＥＴ Ｖ３７２, 2008, Ｐ１４６３-１４７２ * |
| JPN6016009262; ＣＮＳ Ｄｒｕｇｓ Ｖｏｌ． ２５， Ｎｏ． １, 201102, ｐ． ３７-５２ * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017533954A (ja) * | 2014-10-27 | 2017-11-16 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩 |
| KR20170095302A (ko) * | 2014-12-11 | 2017-08-22 | 액테리온 파마슈티칼 리미티드 | 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물 |
| JP2017537129A (ja) * | 2014-12-11 | 2017-12-14 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤 |
| JP2019011343A (ja) * | 2014-12-11 | 2019-01-24 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤 |
| KR101996245B1 (ko) * | 2014-12-11 | 2019-07-05 | 액테리온 파마슈티칼 리미티드 | 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물 |
| JP2021059574A (ja) * | 2014-12-11 | 2021-04-15 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤 |
| JP7033642B2 (ja) | 2014-12-11 | 2022-03-10 | アクテリオン ファーマシューティカルズ リミテッド | 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤 |
| US12336980B2 (en) | 2014-12-11 | 2025-06-24 | Vanda Pharmaceuticals Inc. | Dosing regimen for a selective S1P1 receptor agonist |
| US12409167B2 (en) | 2014-12-11 | 2025-09-09 | Vanda Pharmaceuticals Inc. | Pharmaceutical combination comprising a selective S1P1 receptor agonist |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201308681B (en) | 2017-11-29 |
| BR112013030169A2 (pt) | 2016-08-09 |
| MX2013013781A (es) | 2014-01-08 |
| SG195049A1 (en) | 2013-12-30 |
| EA201391578A1 (ru) | 2014-05-30 |
| IL229448A0 (en) | 2014-01-30 |
| CN103732062A (zh) | 2014-04-16 |
| CA2836480A1 (en) | 2012-11-29 |
| US20140163100A1 (en) | 2014-06-12 |
| EP2713724A4 (en) | 2015-03-11 |
| ECSP13013117A (es) | 2014-06-30 |
| PE20141316A1 (es) | 2014-10-01 |
| PH12013502443A1 (en) | 2019-03-22 |
| CL2013003358A1 (es) | 2014-08-01 |
| CO6811862A2 (es) | 2013-12-16 |
| WO2012162669A1 (en) | 2012-11-29 |
| EP2713724A1 (en) | 2014-04-09 |
| KR20140036257A (ko) | 2014-03-25 |
| AU2012258558A1 (en) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515373A (ja) | 多発性硬化症の治療方法およびミエリン量を保存および／または増加させる方法 | |
| JP5875191B2 (ja) | Ｃｍｔ及び関連障害を処置するための新たな組成物 | |
| TR201806828T4 (tr) | Gut ve hiperürisemi tedavisi. | |
| JP2018526407A (ja) | 特定の患者集団において神経変性障害を処置する方法 | |
| JP2024133735A (ja) | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 | |
| US20220323433A2 (en) | Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor | |
| JP2021512921A (ja) | 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン | |
| JP2015528507A (ja) | 肝性脳症を患う対象の長期生存を改善し、再入院率を低減する方法 | |
| MX2013013125A (es) | Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva. | |
| KR101887561B1 (ko) | 간염 바이러스에 의해 유발된 간 섬유화의 개선을 위한 약학 조성물 | |
| WO2023026247A1 (en) | Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea | |
| JP2014231518A (ja) | 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用 | |
| MX2013013124A (es) | Combinaciones de trospio y estimulantes salivales para el tratamiento de la vejiga hiperactiva. | |
| WO2025078276A1 (en) | Combination of a parp-1 selective inhibitor and temozolimde and its use in the treatment of glioma | |
| Meuwese et al. | Effect of ACAT inhibition on the progression of carotid atherosclerosis in patients with familial hypercholesterolemia The CAPTIVATE study | |
| HK40059411B (en) | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases | |
| MXPA97001528A (en) | Derivatives of 1, 1, 2, - trifenilbut-1-eno to treat alzhei's disease | |
| JP2025521628A (ja) | カルシニューリン阻害剤の間欠的投与のための組成物 | |
| CN121265607A (zh) | 防治脑海绵状血管畸形病变的药物及其应用 | |
| Bankhead | E coli'magic bullet continues to elude scientists. | |
| EP3452172A1 (en) | Compositions and methods for treating viral infection in mammals | |
| HK1104002A (en) | Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150525 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150525 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160308 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160311 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161014 |